Human immunodeficiency virus type 1 (HIV-1) infection is
observed [4] , which may also affect HIV-1 -specific immunity. Potentiation of the antiviral immune response may therefore characterized by an initial acute symptomatic phase followed by a period of asymptomatic chronic infection. This period, lead to a more prolonged containment of the virus. During the last few years, the course of infection has been which may last several years, was initially interpreted as true viral latency. In view of this interpretation, an intervention modified by the use of antiretroviral drugs. Controlled experimental studies using monotherapy or combined therapies with aimed at inducing or boosting the HIV-1 -specific immune response was proposed as a possible means for preventing a reverse transcriptase inhibitors demonstrated a decrease of plasma virus load, an increase of CD4 T cell numbers, and a supposed virus reactivation leading to AIDS [1] . Current views on the pathogenesis of AIDS take into account that virus replireduction of observed clinical events [5, 6] . In addition, preliminary results of anti -HIV-1 vaccination using proteins of viral cation is continuous during infection, with a peak during the acute phase and a progressive increase during the late stages envelope to elicit a specific immune response were promising [7, 8] and encouraged the setting-up of phase II controlled [2, 3] . Rather than being latent, HIV-1 is continuously challenging the immune system, which potently reacts against it, possistudies to evaluate the clinical efficacy of this approach.
To explore both the relevance of postexposure immunotherbly generating a balance that underlies the asymptomatic phase. However, a progressive impairment of immune responses is apy with an HIV-1 subunit and the possible synergism with conventional antiretroviral therapy, we performed a placebocontrolled, double-blind study comparing the use of recombinant (r) gp160 alone, rgp160 in association with zidovudine, HIV classification system [9], the subjects were classified as groups coli-expressed rp24 and rRev protein were purchased from American Bio-Technologies (Cambridge, MA). A1 and A2, having mean CD4 T cell counts between 400 and 600 cells/mL. The group of subjects was followed at the University of Antigen -specific lymphoproliferative responses ( LPRs ). Peripheral blood mononuclear cells (PBMC) were isolated from Rome ''La Sapienza'' and was part of the two-center protocol 809A-205-IT, which included a total of 99 patients. A detailed heparinized venous blood by density gradient centrifugation on Lymphoprep (Nycomed, Oslo) at 800 g for 30 min. Separated description of the clinical results and the main immunologic and virologic results of the entire trial is forthcoming (Pontesilli O, et PBMC (10 6 cells/mL) were cultured in 200 mL of RPMI 1640 with 10% AB human serum that was negative for anti-HIV-1 al., unpublished data).
According to risk factors for HIV-1 infection, the subjects were antibodies (NABI, Miami) in 96-well flat-bottom cell culture plates (Falcon, Lincoln Park, NY) in the presence of 2 mg/mL of rgp160, grouped as follows: 16 male homosexuals, 16 intravenous drug abusers, 2 patients who had received a transfusion with HIV-1-rgp120, rp24, or rRev protein.
To test the proliferative response to recall antigen, we added 50 mg/mL mannoprotein (MP) of Candida infected blood, and 25 patients who had been infected with HIV-1 through heterosexual contact. Candidate patients were screened albicans [11] and 1 Lf/mL tetanus toxoid (TT; Wyeth, Marietta, PA) to the cultures, which were run in triplicate. 1 month before the study to ensure that they met entry criteria. Inclusion criteria and end points were described in detail elsewhere CD3 monoclonal antibody (MAb)-induced lymphoproliferation. Cultures were set up essentially as described above for [10] . In brief, randomized patients had to be asymptomatic (group A) and present a median CD4 T cell count between 400 and antigen cultures, with the following differences: 10 5 PBMC were seeded in each well in 100 mL of RPMI 1640 with 10% fetal 600 cells/mL at screening. Main end points were progression to symptomatic disease (groups B or C) or CD4 T cell count õ200 calf serum added. CD3 MAb OKT3 (Ortho Diagnostic Systems, Raritan, NJ) at 25 ng/mL was added. cells/mL. Serodiagnosis of HIV-1 infection was made by standard ELISA and confirmed by Western blot (Cambridge Biotech, RockCalculation of specific stimulation index (SI). After 6 days of culture at 37ЊC in a humidified 5% CO 2 atmosphere (3 days for ville, MD).
Vaccine product and immunization schedule. The test vaccine, cultures with mitogens), 0.5 mCi of tritiated thymidine (specific activity of 25 Ci/mmol; Amersham, UK) were added to each well. a noninfectious subunit derived from HIV-1 gp160, was produced in a baculovirus expression system in cells of lepidopteran insects, After 24 h (4 h for cultures with mitogens), cells were harvested onto glass fiber filters, and incorporated radioactivity was measured biochemically purified, and adsorbed to aluminum phosphate for final formulation (rgp160, VaxSyn; Protein Sciences, formerly Miin a scintillation counter and expressed as counts per minute (cpm). The SI was calculated by dividing cpm of stimulated cultures croGeneSys, Meriden, CT). The patients were randomized into 3 drug-treatment groups: 1 group received 320 mg of rgp160 intraby cpm of the unstimulated cultures. LPRs to viral antigen were considered significant for SI ú2. This cutoff value was chosen muscularly (im) and oral placebo (rgp160 group), another group received 320 mg of rgp160 im and 250 mg of zidovudine orally because the mean / 2 SD of the SI obtained in cultures of PBMC from HIV-1-seronegative controls for each HIV-1 antigen tested two times a day (zidovudine plus rgp160 group), and the last group received alum im and 250 mg of zidovudine orally two times a was always lower than 2 [12]. The same cutoff has been used by other researchers in similar assays with HIV-1 antigen [13]. day (zidovudine group). During the first 2 years of the study, the patients received 12 injections: The first was on day one, and the CTL assay. Preparation of recombinant vaccinia viruses, target cells and effector cells is described elsewhere [14] . The assay was rest were at months 1-4 and 6 and every 3 months thereafter, up to month 24. The study was for 31 months, including the 1-month done essentially as previously described [15] . Variable numbers of effector cells were mixed with 10 4 51
Cr-labeled target cells in screening period and the 6-month postimmunization period. In the group treated with zidovudine, 5 patients did not complete the V-bottomed microtiter wells in order to obtain effector-to-target ratios of 50:1; 25:1; and 12.5:1 (triplicate cultures). Replicates study (3 had reached one of the established end points, and 2 dropped out due to causes unrelated to the study). In the group with target cells in RPMI 1640 plus 10% fetal calf serum only and 0.1% Triton X-100, respectively, were also set up to determine treated with rgp160, 8 patients did not complete the study (5 had reached one of the established end points, and 3 dropped out due spontaneous and total release. The cells were then incubated for 6 h at 37ЊC and centrifuged at 140 g for 5 min. Supernatant to causes unrelated to the study). In the group treated with zidovudine plus rgp160, 7 patients did not complete the study (4 had (100 mL) was collected from each well, and radioactivity was determined. Results are expressed as follows: % specific 51 Cr rereached one of the established end points, and 3 dropped out due to causes unrelated to the study).
lease Å (experimental release 0 spontaneous release) 1 100/(total release 0 spontaneous release). Percent Env-specific cytotoxicity Immunologic and virologic tests schedule. Lymphoproliferation tests, cytotoxic T lymphocyte (CTL) activity, and cytofluori-Å Env-expressing target release 0 control target release. Lymphocyte phenotyping. Lymphocyte phenotype was determetric analysis of lymphocyte subpopulations were done at baseline and at months 1, 3, 6, 12, 18, 24, and 30. Plasma HIV-1 RNA mined by dual-color direct immunofluorescence with MAb combinations OKT3-fluorescein isothiocyanate (FITC)/OKT4-phoswas quantitated before the vaccination, after 1 month, and at 4 and 24 months.
phatidylethanolamine (PE) and OKT3-FITC/OKT8-PE (Ortho Diagnostic) followed by flow cytometry. HIV-1 antigens. Four recombinant HIV-1 antigens derived from the HIV-1 IIIB sequence were selected for lymphocyte stimulaPlasma HIV-1 RNA determination. Plasma HIV-1 RNA was quantified by a nucleic acid sequence-based assay (NASBA HIVtion assays (rgp160, rgp120, rp24, and rRev protein) as representative of three structural proteins (core and envelope) and one regula-1 RNA QT; Organon Teknika, Boxtel, Netherlands figure 1, the increase of the responder fraction in the rgp160 Results group was significant from the third month (P õ .001). The Response to HIV-1 rgp160. To evaluate the immunization induction of the response to rgp160 in the zidovudine plus rgp160 group was apparently faster, since a significant increase to the injected recombinant antigen, we quantified the fraction of the responder fraction was seen also after 1 month (P Å Longitudinal evaluation of LPRs to HIV-1 antigen. To compare the magnitude of the LPRs to rgp160, rgp120, rp24, .025). When compared with the increase in the responder fraction in the zidovudine group, the responder fraction at each and rRev protein, only the patients who completed the immunization protocol and subsequent follow-up were considered. As time point was significantly higher from the third month in the 2 groups receiving rgp160 (P õ .001). Confirming the faster shown in figure 2A and table 1, no significant variation of the LPR to rgp160 was detected in the zidovudine group. In the kinetics of response, the responder fraction at 1 month in the zidovudine plus rgp160 group was significantly higher than rgp160 group, a significant increase of the LPR to rgp160, compared with the baseline SI, was observed after 3 months that of the zidovudine group at the same time (P Å .039). A transient moderate increase of the responder fraction was seen and in all other subsequent tests (P Å .034 at month 3 and P õ .01 subsequently). A significant increase of LPR to rgp160 also in the zidovudine group only after the first month (P Å .039).
in the zidovudine plus rgp160 group was also observed starting / 9d35$$oc04 08-22-97 16:35:54 jinfa UC: J Infect from the third month (P õ .005 at all time points). As shown for the zidovudine plus rgp160 group and P Å .027 for the zidovudine group, compared with baseline values). by the increase of the responder fraction, the zidovudine plus rgp160 group had a faster response to rgp160, as reflected by Env-specific cytotoxicity. HIV-1 Env-specific CTL activity was measured in a total of 18 patients from the 3 groups an SI that was significantly higher than that of the zidovudine group at 3 and 6 months (P õ .01), when the responder fraction (table 2): 6 (33%) had an initial specific release of ú10% and, therefore, were considered as Env-CTL positive at the start of for the rgp160 group SI was not significantly different from that of the zidovudine group. After the first year of treatment, the study. Modifications of the Env-specific CTL activity were observed during the trial in an equivalent fraction of patients both groups receiving rgp160 had significantly higher LPRs to rgp160 compared with that for the zidovudine group. The LPRs in each group. In detail, 3 patients in each group presented increases of variable duration of Env-specific CTL activity, to rgp160 were persistently elevated in both groups, even though a trend toward reduction was seen 6 months after the which was defined as the appearance of activity in patients initially considered negative or the doubling of pretreatment last injection.
A significant correlation was observed between LPR to activity in patients initially considered positive for Env-specific CTL activity. Variations in Env-specific activity were not assorgp160 and to rgp120 in all studied groups (r Å .684 in the zidovudine group, .962 in the rgp160 group, and .862 in the ciated with immunization with rgp160. CD4 T cell numbers. To monitor the progression of infeczidovudine plus rgp160 group; P õ .001 for all groups), confirming the specificity of the response.
tion in the groups, we evaluated CD4 T cell counts in patients during 30 months of follow-up ( figure 4A ). In the zidovudine LPRs to HIV-1 antigen other than gp160 induced by natural infection were weak and sporadic, which was consistent with plus rgp160 group, a significant increase in CD4 T cell numbers compared with baseline values was observed after 3 months previous observations [12] . At baseline, the median LPRs to rp24 and rRev protein in the study population, regardless of (P Å .024). At that time, the number of CD4 T cells in this group was significantly higher than that for the rgp160 group treatment randomization were 1.25 (range: 0.44 -5.47) and 1.01 (range: 0.41 -6.54), respectively. No significant modification (P Å .023). No other significant modifications of CD4 T cell numbers were observed in the 3 groups; however, both groups of the LPR to rp24 or rRev protein was observed in any of the 3 groups ( figure 2B, C) .
receiving zidovudine maintained mean CD4 T cell counts comparable to baseline values, whereas the rgp160 group showed LPRs to recall antigen and CD3 MAb. We studied the effect of treatment on T cell function measures, namely reslightly lower CD4 T cell counts starting from the sixth month. Plasma HIV-1 RNA. To study the effect of therapy on sponses to recall antigen and to CD3 MAb. A subgroup of 32 patients equally distributed in the 3 groups was evaluated for virus replication, we measured plasma HIV-1 RNA levels in a subgroup of 47 patients equally distributed in the 3 groups. LPRs to MP and TT, and median SIs are shown in figure 3 . No significant modification of the LPR to either microbial In both groups receiving zidovudine, a significant decrease of plasma viremia was observed after 1 month with respect to stimulant was seen in the rgp160 group. An increase of the LPR to both antigens was seen in the zidovudine group; howbaseline levels (P Å .001), and at the same time, plasma virus load was significantly lower in these 2 groups compared with ever, only for MP was the increase significant at months 6 and 18 (P õ .05) compared with baseline values. Even though not the virus load for the group treated with rgp160 alone (P õ .05); however, after 2 years of follow-up, plasma viremia was statistically significant, an early transient increase of LPR to MP was seen also in the zidovudine plus rgp160 group.
comparable to baseline values in all 3 groups (figure 4B). LPR to CD3 MAb is shown in figure 3C and was studied only in the patients who completed the immunization protocol Discussion and subsequent follow-up. As for recall antigen, no modifications of LPR to CD3 MAb were seen in the rgp160 group. A
The correlates of protective immunity during HIV-1 infection are still unclear, but major attention is given to the specific significant increase of LPR to CD3 MAb was observed after 1 year in the other 2 groups receiving zidovudine (P Å .004 cell-mediated immunity [16] . In analogy to other viral infec- tions [17] and considering the association with the initial reducbetween the maintenance of CD4 T cell numbers and the presence of an LPR to HIV-1 p24 in untreated patients during a tion of viremia [18] , HIV-1 -specific CTLs are considered beneficial in containing virus replication and spread. Conversely, short-term follow-up [20] . However a recent analysis suggested that the presence of an LPR to several HIV-1 peptides during LPRs to HIV-1 antigen, which are generally uncommon and weak during the natural infection [12, 19] , do not have a clear the asymptomatic phase is a negative prognostic factor with respect to progression to AIDS [21] . association with virus control. A phase I study of postexposure immunization with rgp160 suggested a beneficial effect of an
The present study confirms the induction of a strong cellmediated immune response to rgp160 in HIV-1 -infected paimmune response to rgp160, measured both as the LPR and as the production of new antibodies with specificity for gp160 tients immunized with rgp160. This response is maintained for at least 6 months after the last injection. Further follow-up of epitopes, as reflected in a slower decline of CD4 T cell numbers with respect to patients who did not respond to the immunizapatients will provide clarification about whether vaccinationinduced immunization is transient or whether the stimulus tion procedure [7] . We have previously observed an association / 9d35$$oc04 08-22-97 16:35:54 jinfa UC: J Infect NOTE. CTL Å cytotoxic T lymphocyte. * No. of patients negative for Env-CTL activity at start of study who became positive at any time during trial and patients with positive Env-specific CTL before treatment and at least 2-fold increase during trial.
caused by the persistence of HIV-1 is sufficient to maintain a strong antiviral response. The LPR to other HIV-1 antigen, encoded for by different genes, is not influenced by the vaccination, as previously reported [7] .
In contrast to previous observations [22] , the Env-specific CTL response is also not significantly influenced by vaccination. In the current study, modifications of Env-specific CTL activity were observed in all 3 groups, suggesting that the specific immunization is not relevant in this respect. Improvement of T cell function associated with treatment with zidovudine might be responsible for a higher frequency of positive CTL assays. Indeed, both groups receiving zidovudine had a transient improvement of T cell function, measured as response to CD3 MAb, mirrored by the expected virus load reduction. The lack of an antigen-specific modification of CTL activity could be found in the modality of immunization, which preferentially activates CD4 T lymphocytes.
The effect on LPRs to recall antigens, such as TT and MP, is less evident since only the group receiving zidovudine showed some increase of LPR to MP with the same kinetics of the improvement of LPR to CD3 MAb. This functional improvement is probably also responsible for the faster response to rgp160 seen in the group receiving both treatments. It may be explained as the result of virus load reduction and thus decreasing toxic effects on immune functions. Alternatively, at least in the case of anti-MP responses, it might also be due to increased clonal expansion of specific CD4 T cells because of the natural stimulation with C. albicans in patients with improved immunologic conditions due to antiretroviral therapy. Treatment with rgp160 did not modify any of the LPRs except those to the immunogen itself. A similar finding was described in a phase I trial in which several doses of rgp160 were compared with the administration of an unrelated vaccine (hepatitis B virus vaccine). Short-term follow-up of those patients revealed that specific responses to gp160 were induced without modification of responses to non -HIV-1 antigen [8] .
Minor changes of CD4 T cells numbers were observed dur- ing the present study even though a trend toward lower set- with viral subunits. A possible explanation of this discrepancy could be found in the induction of immunization to envelope antigen of HIV-1 IIIB in subjects infected by different virus strains.
